DF/HCC Program Affiliation

Neuro-Oncology
Lymphoma and Myeloma

Research Abstract

Dr. Hochberg's interests include Brain Lymphoma, gene therapy for glioma and the use of phase 1 and phase 2 agents to treat glioblastoma. He is the P.I. of an NCI-PO1 (Gene Therapy for Brain Tumors) which explores novel herpes vector systems expressing pro-drug activating transgenes. In addition he has been the PI of an NCI Consortium award to the Massachusetts General Hospital for the study of novel therapies of malignant brain tumors. Current research activities include the evaluation of risk factors for the development and progression of brain lymphoma including analyses of subtle alterations of cell-mediated immunity that might predispose to tumor development in "immunocompetent" individuals, the role of IgH rearrangement, the role of sustained EBViral infections (E. Kieff). Translational trials include therapies employing novel viral vectors (herpes, Adenoviral) expressing tk and interferon transgenes; novel phase 1 agents including camptothecins, antifols and angiogenesis inhibitors. These trials make use of novel surrogates of drug delivery including microdialysis probes and imaging of tumor blood flow, blood volume and permeability.

Publications

View All Publications